Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT02200562 · ClinicalTrials.gov registry record · Phase 1
Ipilimumab and Dabrafenib in the 1st Line Tx of Unresectable Stage III/IV Melanoma
A Phase 1 study, sponsored by University of Utah.
- Terminated
- Registry status
- Phase 1
- Development phase
- 6
- Enrollment target
NCT02200562 is a Phase 1 study that was terminated before completion, run by University of Utah. The registered enrollment target is 6 participants.
The verdict
NCT02200562, a Phase 1 study, was terminated before completion, sponsored by University of Utah.
- TERMINATED
- Registry status
- Phase 1
- Development phase
- 6 participants
- Enrollment target
Study Summary
Phase I/II study of ipilimumab concurrent ipilimumab and dabrafenib as first line treatment in Stage III or IV melanoma. Assessing safety of Ipilimumab and dabrafenib in combination. Also, assessing disease control rates.
Interventions
- DRUG ipilimumab and dabrafenib
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 6 participants |
| Start Date | 2014-12 |
| Est. Completion | 2017-01-20 |
| Phase | Phase 1 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT02200562
The ClinicalTrials.gov registry entry for NCT02200562 describes a study currently listed as terminated, categorized as Phase 1. The registered enrollment target is 6 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is University of Utah, which has 818 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 1 intervention - of which ipilimumab and dabrafenib is the first listed.
NCT02200562 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT02200562 about?
NCT02200562 is a clinical study titled "Ipilimumab and Dabrafenib in the 1st Line Tx of Unresectable Stage III/IV Melanoma". Phase I/II study of ipilimumab concurrent ipilimumab and dabrafenib as first line treatment in Stage III or IV melanoma. Assessing safety of Ipilimumab and dabrafenib in combination. Also, assessing disease control rates.
What is the current status of trial NCT02200562?
This trial is currently terminated. It is a Phase 1 study. The enrollment target is 6 participants. The study started on 2014-12. Estimated completion is 2017-01-20.
What interventions are being tested in trial NCT02200562?
The interventions under investigation include: ipilimumab and dabrafenib (DRUG).
Who is sponsoring clinical trial NCT02200562?
This trial is sponsored by University of Utah, which has 818 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.